

























































CYP154C5 Regioselectivity in Steroid Hydroxylation
Explored by Substrate Modifications and Protein
Engineering**
Paula Bracco,[a] Hein J. Wijma,[b] Bastian Nicolai,[a] Jhon Alexander Rodriguez Buitrago,[d]
Thomas Klünemann,[c] Agustina Vila,[a] Patrick Schrepfer,[d] Wulf Blankenfeldt,[c, d]
Dick B. Janssen,[b] and Anett Schallmey*[d]
CYP154C5 from Nocardia farcinica is a P450 monooxygenase
able to hydroxylate a range of steroids with high regio- and
stereoselectivity at the 16α-position. Using protein engineering
and substrate modifications based on the crystal structure of
CYP154C5, an altered regioselectivity of the enzyme in steroid
hydroxylation had been achieved. Thus, conversion of proges-
terone by mutant CYP154C5 F92A resulted in formation of the
corresponding 21-hydroxylated product 11-deoxycorticosterone
in addition to 16α-hydroxylation. Using MD simulation, this
altered regioselectivity appeared to result from an alternative
binding mode of the steroid in the active site of mutant F92A.
MD simulation further suggested that the entrance of water to
the active site caused higher uncoupling in this mutant.
Moreover, exclusive 15α-hydroxylation was observed for wild-
type CYP154C5 in the conversion of 5α-androstan-3-one,
lacking an oxy-functional group at C17. Overall, our data give
valuable insight into the structure–function relationship of this
cytochrome P450 monooxygenase for steroid hydroxylation.
Introduction
Cytochrome P450 monooxygenases (P450s or CYPs) are
hemoproteins carrying a heme b molecule covalently linked to
a cysteine side chain.[1] From a biocatalytic perspective, they are
remarkable enzymes as they are able to catalyze the selective
hydroxylation of non-activated carbon atoms using molecular
oxygen.[2,3] For the activation of molecular oxygen during the
catalytic cycle, they require electrons – from NAD(P)H – which
are in most cases delivered to the monooxygenase by addi-
tional redox partners.[4] One of the most important industrial
uses of these cytochrome P450 monooxygenases is their
application in steroid synthesis in the pharmaceutical industry
due to their remarkable selectivity in steroid hydroxylation.
Well-known examples include the 11β-hydroxylation of 11-
deoxycortisol (Reichstein S) to hydrocortisone by Curvularia sp.
or the conversion of progesterone to cortisone by Rhizopus
sp.[5–8] Though P450s are already applied on industrial scale,
there is always the need for yield improvement, including the
increase in hydroxylation specificity (e.g., fewer by-products),
the need for an altered selectivity of the enzyme to also
hydroxylate, for example, new sites in a known substrate or the
adaptation of a known P450 to a new substrate.[9] In that
respect, protein engineering has proven to be a powerful tool
to alter enzyme characteristics such as activity and selectivity.
One example, reported by Kille et al., is the generation of
P450BM3 mutants hydroxylating testosterone selectively either
at 2β- or 15β-position, while the starting mutant, P450BM3
F87A, forms a 1 :1 mixture of 2β- and 15β-
hydroxytestosterone.[10] In this case, mutants were generated by
iterative combinatorial active-site saturation mutagenesis, a
protein engineering approach that is significantly facilitated by
the availability of structural information for a given protein.
Recently, the crystal structure of CYP154C5, a cytochrome
P450 monooxygenase from Nocardia farcinica, was elucidated
in the presence of four steroid substrates.[11] This enzyme
catalyzes the highly regio- and stereoselective hydroxylation of
different pregnans and androstans producing exclusively the
corresponding 16α-hydroxylated products.[12] As the natural
redox partners of this P450 monooxygenase are unknown,
putidaredoxin (Pdx) and putidaredoxin reductase (PdR) from
Pseudomonas putida can be applied in bioconversions to supply
CYP154C5 with electrons. The active site pocket of CYP154C5
forms a hydrophobic “tube” with two opposite polar regions at
both ends. These polar regions are occupied by Gln239 and
Gln398 forming hydrogen bond interactions with the hydroxy
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or ketone functionalities of steroids at positions C3 (via water
molecules) and C17.[11] Additionally, several hydrophobic inter-
actions between enzyme and steroid substrate within the active
site could be identified. With the help of the crystal structure
the remarkably high regio- and stereoselectivity of CYP154C5
towards steroids 1–6 (Figure 1) was explained.[11]
With the future goal to modify the enzyme’s regioselectivity
in steroid hydroxylation reactions, we herein aimed to explore
the selectivity of CYP154C5 in more detail based on the
previously obtained structural insight. To this end, selected
active-site residues of CYP154C5, mediating important enzyme-
substrate interactions, were mutated by site-directed muta-
genesis, and resulting mutants were applied in bioconversions
with steroids 1–6. In a complementary approach, steroid
substrates lacking oxyfunctional groups at C3 and C17, which
otherwise enable hydrogen bonding with active site residues of




Based on the CYP154C5 crystal structure and a detailed analysis
of the enzyme active site in the presence of different steroid
substrates,[11] four active-site residues have been identified to
play an important role in steroid binding. Among them are the
two glutamines at positions 239 and 398 forming hydrogen
bonds with the carbonyl or hydroxy groups at C3 (via a water
molecule) and C17 of the steroid substrates (Figure 2). More-
over, residues M84 and F92 are involved in hydrophobic
interactions with the steroid backbone. Specifically, M84
interacts with C11 and C12 of ring C as well as methyl
substituents (C18 and C19) on the steroid backbone, while
residue F92 forms hydrophobic contacts with C5, C6, C7, and C8
of ring B.[11] Thus, residues M84, F92, Q239 and Q398 were
selected for mutagenesis to investigate their impact on steroid
binding and CYP154C5's selectivity in steroid conversions. To
this end, single alanine mutations were prepared using site
directed mutagenesis. Afterwards, wild-type CYP154C5 as well
as mutants M84A, F92A, Q239A and Q398A were heterologously
produced in Escherichia coli C43(DE3) and purified by anion
exchange and affinity chromatography (Figure S1 in the
Figure 1. Chemical structures of previously tested (1–6)[11,12] and five new steroid substrates (7–11) used in bioconversions with CYP154C5 (wild-type and
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Supporting Information). Similarly, redox partners Pdx and PdR
from P. putida, which are required for P450 activity, were
produced in E. coli C43(DE3) and subsequently purified by anion
exchange and hydrophobic interaction chromatography (Fig-
ure S1).
Steroid conversion by CYP154C5 mutants
In order to analyze the influence of the different mutations on
steroid binding and catalysis by CYP154C5, dissociation con-
stants (KD), turnover numbers (TONs) and coupling efficiencies
of the mutants towards steroids 1–6 were determined. In the
absence of substrate, P450 enzymes exhibit an absorbance
maximum around 420 nm. Upon substrate binding, a water
molecule is removed as the sixth ligand at the heme iron.[13]
This causes a spin shift of the heme iron which, in type I
spectral changes, involves a shift of the P450 absorbance
maximum to approximately 390 nm. From the peak-to-trough
difference in absorbance (ΔA) between P450 with high-spin
iron (A390) and low-spin iron (A420) dissociation constants can be
inferred. Using the four different CYP154C5 mutants and
steroids 1–6, KD values for almost all combinations could be
determined (Table 1; respective plots are displayed in Figur-
es S2–S6). Some mutants, however, yielded only a partial or no
spectral shift upon substrate addition (Figure S7), even at high
steroid concentration, hampering KD determination. A missing
spectral shift upon substrate addition could indicate that the
respective steroid does not bind anymore in the mutated active
site of CYP154C5. It is also possible, however, that due to the
mutation in the active site, the bound substrate is not
positioned anymore close to the heme iron to displace the
water molecule as the sixth ligand.
Notably, obtained KD values of the alanine mutants were in
many cases higher compared to wild-type CYP154C5, indicating
a substantial influence of the mutated active-site residues on
steroid binding. The main exception is CYP154C5 Q239A for
which the obtained KD values were even lower than for wild-
type CYP154C5. This suggests a positive influence of mutation
Q239A on steroid binding. The exact molecular reasons,
however, are difficult to anticipate, as the exchange of
glutamine by alanine at this position will actually result in a loss
of a hydrogen bond, via a water molecule, to the oxygen atom
at C3 of the steroids. Here, a crystal structure of CYP154C5
Q239A with one of the steroids 1–6 bound in the active site
could be solved in the future to gain deeper insight.
Furthermore, binding of pregnenolone (1) and progesterone (3)
to CYP154C5 was hardly affected by amino acid exchange
Q398A, whereas significantly higher KD values were obtained for
all other steroid substrates. Removal of the glutamine side chain
in CYP154C5 Q398A leads to a loss of a hydrogen bond to the
C17-substituent oxygen of the steroid substrate, and generates
space that could result in a possible movement of steroids 2, 4,
5 and 6 in the active site. In contrast, steroids 1 and 3 carry a
more spacious acetyl side chain at C17, which could fill this
space resulting in a tighter binding. Interestingly, mutation
M84A in CYP154C5 affected substrate binding the most among
all tested variants. More than 100-fold lower binding affinities
compared to wild-type CYP154C5 were obtained with androste-
nedione (4) and testosterone (5). Additionally, no spectral shifts
of CYP154C5 M84A were observed with steroids 1 and 6, while
substrates 2 and 3 induced only partial shifts. This clearly
emphasizes the importance of position M84 for steroid binding
and correct positioning within the active site of CYP154C5.
Turnover numbers and coupling efficiencies of the purified
mutants were determined in the conversion of steroids 1–6,
together with Pdx and PdR as redox partners (Tables 2 and 3).
Mutants CYP154C5 M84A, CYP154C5 F92A and CYP154C5
Q398A exhibited significantly decreased TONs in comparison to
the wild-type enzyme, independent of the used substrate, while
for mutation Q239A the TONs were less affected (Table 2). This
Figure 2. Superposition of the active sites of the four CYP154C5 – steroid
complexes (PDB IDs: 4J6B, 4J6C, 4J6D and 4JBT) with the four amino acid
residues (M84, F92, Q239 and Q398) involved in steroid binding.
Table 1. Dissociation constants (KD) of CYP154C5 wild type and mutants for steroid substrates 1–6. KD values were determined at 30 °C for the His-tagged
CYP154C5 mutants using the quadratic tight-binding equation.[14] All values are the result of duplicate measurements given as mean�SD.
KD [nM]
Substrate Wild-type M84A F92A Q239A Q398A
pregnenolone (1) 62�14 –[a]   /+ [b] <1 65�21
dehydroepi-androsterone (2) <1   /+ [b] 1017�32 <1 687�43
progesterone (3) 15�10   /+ [b] 209�12 <1 34�21
androstene-dione (4) 12�7 3130�234 512�17 <1 572�151
testosterone (5) 18�10 5710�161 1481�33 <1 747�45
nandrolone (6) 100�17   [a]   /+ [b] 13�6   [a]
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is in general agreement with the observed higher KD values
obtained for mutants CYP154C5 M84A, CYP154C5 F92A and
CYP154C5 Q398A. Interestingly, CYP154C5 M84A converted
pregnenolone (1) to a small extent even though no shift from
low to high spin could be detected. Such a behavior was
previously observed in the case of cytochrome P450 from
Bacillus megaterium, CYP106A2, where no change in absorbance
was obtained upon addition of deoxycortisone (DOC) although
this substrate is converted by this enzyme producing 15β-
hydroxydeoxycortisone.[15] Simgen et al., however, proved by
FTIR spectroscopy using the stretch vibration of the heme iron
CO-ligand that DOC indeed enters the active site and binds
close to the heme prosthetic group.[15]
Similarly, obtained coupling efficiencies of the CYP154C5
mutants in the conversion of steroids 1–6 were, in many cases,
also negatively affected (Table 3). This is especially evident for
substrates pregnenolone (1) and progesterone (3) as well as for
coupling efficiencies of mutant CYP154C5 M84A with all tested
steroids. In contrast, coupling efficiencies of CYP154C5 F92A
with nandrolone (6), CYP154C5 Q239A with 3, 5 and 6 as well
as coupling efficiencies of CYP154C5 Q398A with testosterone
(5) are still similar to the wild-type values.
In almost all cases, the CYP154C5 mutants still formed the
corresponding 16α-hydroxylated products in steroid conver-
sions of 1–6. Hence, regioselectivity of the single mutants was
generally not affected, except for the conversion of progester-
one (3) by mutant CYP154C5 F92A. Here, formation of a second
hydroxylation product was observed (Figure S12), which was
identified as 11-deoxycorticosterone (hydroxylation at position
21) by NMR analysis (Scheme 1). Both products, 16α- and 21-
hydroxylated progesterone, were produced in a ratio of 4 :1 by
CYP154C5 F92A. Hydroxylation of progesterone as well as 17α-
hydroxyprogesterone at C21 yielding 11-deoxycorticosterone
and 11-deoxycortisol, respectively, are important steps in
adrenal steroidogenesis required for the synthesis of glucocorti-
coids and mineralocorticoids. In human, CYP21A2 is the
responsible enzyme catalyzing this step. Interestingly, for
CYP21A2 the formation of 16α-hydroxyprogesterone as side
product has been reported as well.[16] Moreover, exchange of
Val359 by alanine yielded a mutant with significantly increased
hydroxylation in 16α position resulting in a ratio of 21-
hydroxyprogesterone to 16α-hydroxyprogesterone of 60 :40,
while mutant CYP21A2 V359G gave even 90% 16α-
hydroxyprogesterone.[17]
To reveal the structural basis of the change in regioselectiv-
ity of mutant CYP154C5 F92A in progesterone hydroxylation,
this enzyme-substrate complex was studied by computational
tools.
Table 2. Turnover numbers (TONs) of CYP154C5 wild type and mutants in the conversion of steroids 1–6. TONs were determined at 30 °C based on the
highest observed substrate consumption rate in each reaction. Measurements were performed in duplicate. Values are given as mean�SD.
TON [μmol substrate consumed μmolP450
  1min  1]
Substrate Wild-type[a] M84A F92A Q239A Q398A
pregnenolone (1) 4.47�0.36 0.20�0.00 0.85�0.16 2.48�0.02 0.93�0.14
dehydroepi-androsterone (2) 5.1�0.11 0.75�0.09 1.48�0.26 2.07�0.24 1.22�0.21
progesterone (3) 5.7�0.22 2.52�0.12 1.02�0.07 4.33�0.05 1.45�0.07
androstene-dione (4) 3.14�0.36 1.53�0.14 1.68�0.07 2.42�0.05 1.77�0.19
testosterone (5) 1.77�0.06 0.70�0.05 1.75�0.12 1.32�0.12 0.57�0.09
nandrolone (6) 1.33�0.10   [b] 1.33�0.09 1.28�0.02   [b]
[a] Data taken from ref. [11] for comparison. [b] No conversion observed.
Table 3. Coupling efficiencies of CYP154C5 wild type and mutants in the conversion of steroids 1–6. Measurements were performed in duplicate. Values are
given as mean�SD.
Coupling efficiency [%]
Substrate Wild-type[a] M84A F92A Q239A Q398A
pregnenolone (1) 68�1 34�6 40�8 27�5 53�2
dehydroepi-androsterone (2) 86�5 60�7 55�0 90�4 41�6
progesterone (3) 84�3 34�1 22�9 38�8 46�0
androstene-dione (4) 83�1 23�14 64�3 66�6 51�7
testosterone (5) 62�5 39�4 46�3 64�8 68�1
nandrolone (6) 40�7   [b] 52�18 34�3   [b]
[a] Data taken from ref. [11] for comparison. [b] No conversion observed.
Scheme 1. Conversion of progesterone (3) by CYP154C5 wild type and
mutants M84A, F92A, Q239A and Q398A together with redox partners Pdx
and PdR yielding 16α-hydroxyprogesterone. Only in the case of CYP154C5





1102ChemBioChem 2021, 22, 1099–1110 www.chembiochem.org © 2020 The Authors. ChemBioChem published by Wiley-VCH GmbH
Wiley VCH Mittwoch, 10.03.2021


























































Modeling of CYP154C5 F92A
A structural model of the compound I intermediate of the F92A
mutant was generated and used in docking and molecular
dynamics simulations. As a reference, a crystal structure of wild-
type CYP154C5 with progesterone (3) bound was converted to
the compound I state (Figure 3A) and subjected to docking as
well.[11] The docking simulations with the F92A mutant
suggested two possible binding orientations for substrate 3.
One orientation is similar to the one found in the crystal
structure (Figure 3C), whereas the second is clearly different:
progesterone is reoriented with its A and B ring now occupying
the space created by the F92A mutation and only the hydro-
gens of carbon 21 are close to the reactive oxygen of
compound I (Figure 3B). This alternative orientation of the
substrate would cause extreme steric hindrance, if F92 would
remain in the position that is observed in all X-ray structures;
the aromatic ring of F92 would have to interlock with the A or B
ring of the steroid.
The first step in P450-catalyzed hydroxylation is the
abstraction of a hydrogen atom from the substrate by the
electrophilic oxygen of the compound I intermediate.[18] The
predicted reactivity of different enzyme-substrate complexes
was therefore examined by molecular dynamics (MD) simula-
tions with scoring of near-attack conformations (NACs) in which
substrate hydrogens approach the oxygen of the compound I
intermediate (Figure S8). For each complex, three independent
22 ns MD simulations were performed. The enzyme-substrate
complexes were stable (Figure 4) and the simulations gave
reproducible results. In simulations of progesterone (3) in
complex with wild-type CYP154C5, both the 16α and 21
hydrogen atoms stayed close to the reactive oxygen atom
(Figure 4A). The overall X-ray structure was maintained and
high percentages of NACs were found for both positions
(Table 4). The observation that only 16α hydroxylation took
place with the wild-type enzyme is in agreement with the
higher reactivity of this secondary carbon atom compared to
the primary carbon atom at position 21,[19] even though the
latter might be influenced by the flanking carbonyl group.
With the substrate oriented in the F92A mutant like it is in
the wild-type enzyme, the distances and NAC percentages for
the 16α and 21 hydrogens calculated from the simulations
were similar to those found with the wild-type CYP154C5
(Figure 4C). In contrast, MD simulations of the F92A mutant
with progesterone (3) bound in the alternative orientation
(Figure 4B) showed that in this case only the 21 position can
undergo oxidation. The distance between the 16α hydrogen
and the reactive oxygen is predicted to exceed 6 Å, making
hydrogen abstraction impossible and only the 21 hydrogens
gave significant levels of NACs (Table 4). Thus, the modeling
suggests that the F92A mutation provides an additional
progesterone (3) binding mode that is particularly suitable for
oxidation at the 21 position. Also Pallan et al. suggested that
two alternative binding modes of 3 in CYP21A2’s active site are
responsible for the formation of 21- and 16α-hydroxylated
products by this enzyme based on an observed partial burst in
Figure 3. The modeled orientations of progesterone (3) can explain selective
oxidations at the 21 and 16α positions. For each structure, ten MD snapshots
are shown. Carbons 16 and 21 of the progesterone substrate are indicated
with a black-and-white checkered pattern. A) Wild-type CYP154C5, where
both the hydrogens at the 21 and 16α position are close to the compound I
oxygen, thus suggesting the result will be selective oxidation of the more
reactive secondary carbon atom 16 instead of the primary carbon atom 21.
B) F92A with 3 bound in an alternative orientation, in which only oxidation
at the 21 position is possible. C) F92A is also predicted to occur with 3
bound in a wild type-like orientation, enabling 16α oxidation.
Figure 4. Distance of the substrate‘s (3) hydrogen atoms to the oxygen of
compound I. Because there are three identical 21 hydrogen atoms per
substrate, only the shortest distance is shown at each time-point. Also for
clarity, for each modeled enzyme substrate complex, only the first out of the
three independent MD simulations is shown. A) Wild-type CYP154C5 with
progesterone bound. B) CYP154C5 F92A with progesterone bound in the
alternative orientation; C) CYP154C5 F92A with progesterone bound in the
native-like orientation.
Table 4. Near attack conformations of wild-type CYP154C5 and mutant F92A with progesterone as ligand. Potential oxidation sites of progesterone are
given.
Structure simulated by molecular dynamics NACs during MD simulation [%]
16α oxidation 21 oxidation
WT+progesterone 22 7
F92A+progesterone in alternative orientation[a] 0 42
F92A+progesterone in native like orientation[b] 2 5




1103ChemBioChem 2021, 22, 1099–1110 www.chembiochem.org © 2020 The Authors. ChemBioChem published by Wiley-VCH GmbH
Wiley VCH Mittwoch, 10.03.2021


























































pre-steady state kinetics.[20] Furthermore, two alternative orien-
tations for progesterone (3) binding have also been observed
for CYP260A1 by molecular docking, explaining the low
selectivity of this CYP in progesterone conversion. Moreover,
through targeted mutagenesis of active-site residue S276, one
or the other binding orientation could be suppressed yielding
two highly regio- and stereoselective CYP260A1 mutants, which
formed either 1α- or 17α-hydroxyprogesterone selectively.[21]
Furthermore, CYP154C5 F92A with progesterone (3) also
gave the highest uncoupling (Table 3). Uncoupling is commonly
observed with P450 mutants and is a highly relevant challenge
as it hinders their use in applied catalysis.[22] We found that
substrate 3 is more mobile in the active site of mutant F92A.
The root-mean-square fluctuations (RMSF) of this substrate are
higher in the mutant than in wild-type CYP154C5 (Figure S9).
This suggests that the shape-complementarity between enzyme
and substrate is not optimal in the mutant. Also, while in the
case of the wild type, the closest water stayed at a 7 Å distance
from the reactive oxygen during the entire MD simulations (in
agreement with a good enzyme-substrate shape complemen-
tarity), with mutant F92A a water molecule did approach the
reactive oxygen for both substrate orientations (Figure 5). Some
of the observed distances are less than 2 Å. Moreover, the
intruding water forms a H-bond with the reactive oxygen. While
the encroaching water does not drive out the substrate
(Figures 4, S10 and S11), the H-bonding should change the
reactivity of compound I. Uncoupling at the stage of compound
I (the oxidase shunt) involves the addition of two protons and
two electrons after which the reactive oxygen dissipates to
water. Mechanistically, it seems unlikely that the water molecule
would protonate compound I (at least not before the latter has
been further reduced by one or two electrons), as compound I
already has a strongly positive charge. It seems more feasible
that the H-bonding would decrease the reactivity of compound
I or increase its redox potential, which in either case would
increase the chance that compound I becomes reduced before
the substrate had the time to react. Theoretical modeling found
that H-bonding to the sulfur that coordinates the iron has a
strong effect on reactivity.[23,24] H-bonding by water to the
reactive oxygen atom of compound I is expected to have even
stronger effects, as it is extremely close to the site of the
reaction.
Bioconversions of new steroid substrates by wild-type
CYP154C5
Instead of introducing mutations, an alternative approach to
study the enzyme’s selectivity is the selection of steroid
substrates that are either lacking key functional groups for the
enzyme-substrate interaction or that are carrying new features.
Hence, based on the known CYP154C5-steroid complex
structures, five new steroid substrates were selected. As
previously reported, oxyfunctional groups at C3 and C17 were
shown to form hydrogen bond interactions with residues Q239
(via a water molecule) and Q398, respectively.[11] Therefore,
steroid substrates lacking one (10 and 11) or both (9) oxyfunc-
tional groups, as well as steroids containing a larger side chain
at position C17 (7 and 8) were chosen to be tested in
bioconversions with wild-type CYP154C5 (Figure 1).
Initially, small-scale reactions employing whole cells or cell-
free extract of E. coli containing wild-type CYP154C5, Pdx and
PdR were carried out in order to investigate if compounds 7–11
are converted. Reactions employing whole cells or cell free
Figure 5. Distance between the reactive oxygen atom of compound I and
the nearest water molecule during MD simulation. The results from three
independent MD simulations are shown with a black continuous line (first
simulation), with blue long dashes (second simulation), and with gray short
dashes (third simulation). A) Wild-type CYP154C5 with 3 bound. B)
CYP154C5 F92A with 3 bound in the alternative orientation; C) CYP154C5
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extract of E. coli containing only Pdx and PdR were used as
negative controls under the same reaction conditions. No
conversion of finasteride (7) and etiadienic acid ethyl ester (8)
by CYP154C5 could be observed, neither employing whole cells
nor cell-free extract. This is probably the result of the larger
side-chain at C17 preventing binding of the steroids in the
enzyme’s active site. This is further supported by the fact that 7
and 8 did not induce any spectral shift during KD measurements
(data not shown). Similarly, CYP154C3 from Streptomyces
griseus, a homologue of CYP154C5 hydroxylating steroids
selectively at 16α position as well, is also unable to convert
steroids with bulky substituents at the D ring.[25] In the case of
ethioallocholane (9) conversion by CYP154C5, a possible
product peak was identified by GC-MS (Figure S15) though
conversion was too low for product isolation. A NIST-library
search suggested a steroid-related structure for this product.
Additionally, steroid 9 induced a partial spectral shift of
CYP154C5 during KD measurements with a high-spin species
content of roughly 50% (Figure S7–G). These results suggest
that ethioallocholane (9) is indeed converted by CYP154C5 but
further tests will be necessary to identify the formed product. In
contrast, conversion of 3-deoxydehydroepiandrosterone (10)
led to the formation of several products (Figure S16), indicating
that the regio- and/or stereoselectivity of CYP154C5 was
altered. Moreover, conversion of 5α-androstan-3-one (11) by
CYP154C5 resulted in one hydroxylated product (Figure S20).
In order to elucidate the structures of formed products,
whole-cell bioconversions were performed on preparative scale
for substrates 3-deoxydehydroepiandrosterone (10) and 5α-
androstan-3-one (11). Similar to the results obtained on
analytical scale, several products were formed in the prepara-
tive-scale conversion of 10 by wild-type CYP154C5. Of these
products, two were obtained in sufficient amount and purity for
subsequent NMR analysis (see the Supporting Information for
NMR spectra). Results revealed that 16α-hydroxy-3-deoxydehy-
droepiandrostendione was formed as the main product
(Scheme 2). Interestingly, the second purified product seems to
be the result of a double hydroxylation as indicated by GC-MS
and NMR data (Figures S18 and S19). The exact hydroxylation
positions, however, could not be determined due to low
product quantities. Preliminary docking studies with 3-deoxy-
dehydroepiandrosterone (10) and the compound I model of
wild-type CYP154C5 suggest position 4β as potential hydrox-
ylation site in addition to the observed 16α-hydroxylation
(Figure S12A). Similarly, also product 16α-hydroxy-3-deoxydehy-
droepiandrosterone was docked in the active site with position
4β as potential hydroxylation site (Figure S12B), which would
ultimately result in a double hydroxylation of 10. Furthermore,
position 2α was identified as potential additional hydroxylation
site when using 4β-hydroxylated 10 as docking substrate
(Figure S12C). Even though these docking poses were only
obtained in silico, they can give a first indication for potential
hydroxylation sites of the other observed products.
In contrast, the product formed in the preparative-scale
conversion of 5α-androstan-3-one (11) by CYP154C5 was
identified as 15α-hydroxy-5α-androstan-3-one by NMR (Fig-
ure S21 and Scheme 2; details on the assignment of the
hydroxylation product are given in the Supporting Information).
This result indicates a change in CYP154C5’s regioselectivity in
the conversion of 11, likely caused by the lack of the functional
group at position C17 and/or the saturated A-ring of the steroid
substrate. To gain structural insight into the altered regioselec-
tivity of wild-type CYP154C5 in the conversion of 11, the P450
was co-crystallized with this steroid. The overall structure of
CYP154C5 is very similar to the previously determined
CYP154C5 structures with Cα-RMSD values of 0.20–0.37. The
electron density of the ligand and the derived model indicate
that 5α-androstan-3-one (11) binds in a similar position as
androstenedione (4) and testosterone (5; Figure 6), the latter
being hydroxylated in 16α position by wild-type CYP154C5.
Interestingly, however, C15 of steroids 4, 5 and 11 in the
corresponding crystal structures of CYP154C5 are in a similar
position as C16 of pregnenolone (1) and progesterone (3;
Figure 6 A), which are also hydroxylated in 16α position by
Scheme 2. Conversion of 3-deoxydehydroepiandrosterone (10) and 5α-androstan-3-one (11) by wild-type CYP154C5 together with redox partners Pdx and
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wild-type CYP154C5. Hence, the crystal structure alone cannot
explain the observed hydroxylation of 5α-androstan-3-one (11)
in 15α-position. Therefore, MD simulations (10 trajectories of
22 ns each) of the compound I state of the CYP154C5 structure
with 11 bound in the active site have been performed with
scoring of NACs as mentioned before (Figure S13). This way,
predicted NAC percentages of 0.31% for C15 and 15.8% for C16
were obtained. This confirms that C15 can be reached in
productive conformations by the oxygen of compound I, even
though the probability for attack of C16 seems to be higher as
judged by distance. The question, why only 15α-hydroxy-5α-
androstan-3-one is observed as product in conversions of 11 by
CYP154C5, cannot finally be solved but might be caused by a
higher reactivity of C15 compared to C16. Here, quantum
mechanical calculations could be performed in the future to
reveal further insight.
Additionally, KD values, TONs and coupling efficiencies for
wild-type CYP154C5 in the conversion of 3-deoxydehydroepian-
drosterone (10) and 5α-androstan-3-one (11) were determined.
CYP154C5 exhibited a rather high affinity towards substrates 10
and 11 with KD values of 94�52 and 20�16 nM, respectively.
In contrast, coupling efficiencies are dramatically decreased in
both cases resulting in only 7�6 and 26�10% for steroids 10
and 11, respectively. Similarly, obtained TONs (0.67�0.17 and
0.77�0.17 min  1 for 10 and 11, respectively) are also rather low
compared to steroids 1–6. This suggests that steroid conversion
by CYP154C5 is indeed significantly affected if one of the
oxyfunctional groups at C3 or C17 of the steroid backbone, and
hence the corresponding hydrogen bond, is missing. On the
other hand, TONs of wild-type CYP154C5 for conversion of 10
and 11 were determined for the whole-cell system and not
isolated enzyme. Hence, the resulting data is not directly
comparable to TONs determined in the conversion of steroids
1–6.
Conclusion
With our study, we were able to demonstrate experimentally
that the previously reported high regioselectivity of CYP154C5
is dependent on the presence of oxyfunctional groups at C3
and C17 of the steroid substrate, as products with new
hydroxylation sites were obtained in reactions with steroids
lacking one of those substituents. Here, hydroxylation of 5α-
androstan-3-one in 15α position is especially interesting, as 15α
hydroxylation of steroids by bacterial cytochrome P450 mono-
oxygenases has only been reported once so far, in the
conversion of testosterone and dehydroepiandrosterone by
specific mutants of CYP102A1 from B. megaterium.[26] In
contrast, the replacement by alanine of active site residues
Q239 and Q398 in CYP154C5, which have been shown to
interact with the oxyfunctional groups through hydrogen
bonding, did not alter the enzyme’s regioselectivity but had a
negative impact on catalytic efficiency. Similarly, mutagenesis
of residues M84 and F92, which form hydrophobic interactions
with the steroid backbone, resulted in reduced turnover
numbers and coupling efficiency as well as higher dissociation
constants for most steroid substrates tested. This was especially
evident for mutant M84A, which confirms the importance of
residue M84 for delimiting the active site pocket and confining
the steroid in a catalytically active position. Moreover, mutation
F92A appeared to enable a second binding orientation of
progesterone in the enzyme active site resulting in C21
hydroxylation. Overall, our data demonstrate the feasibility for
future modification of CYP154C5 regioselectivity by protein
engineering and give valuable insight into the structure–
function relationship of this cytochrome P450 monooxygenase
for steroid hydroxylation.
Experimental Section
Substrates and chemicals: Pregnenolone (1), progesterone (3),
testosterone (5) and cholesterol were purchased from Sigma–
Aldrich. Dehydroepiandrosterone (2), androstenedione (4), nandro-
lone (6), finasteride (7), etiadienic acid ethyl ester (8), ethioallocho-
lane (9), 3-deoxydehydroepiandrostendione (10) and 5α-androstan-
3-one (11) were purchased from Steraloids Inc. (Newport, USA).
Cytochrome c from horse heart, formate dehydrogenase from
Candida boidinii, superoxide dismutase, catalase from bovine liver
and hydroxypropyl β-cyclodextrine were purchased from Sigma–
Aldrich. All solvents and other chemicals required for the experi-
ments were obtained from Roth (Karlsruhe, Germany) or Sigma–
Aldrich and used without further purification.
Bacterial strains and plasmids: E. coli DH5α (Invitrogen) was used
for genetic manipulations, while E. coli C43(DE3) (Lucigen, Mid-
dleton, WI, USA) was used for recombinant gene expressions.
Plasmid pET28a(+) was purchased from Novagen (EMD Biosciences,
San Diego, CA, USA). Preparation of plasmid pACYCcamAB for
coexpression of putidaredoxin reductase (CamA or PdR) and
putidaredoxin (CamB or Pdx) from P. putida was described
elsewhere.[27] Preparation of plasmid pIT2cyp154C5 was described
elsewhere.[12] The gene of CYP154C5 was subcloned from vector
pIT2cyp154C5 into pET28a(+) using restriction sites NdeI and
HindIII. The resulting plasmid was named pET28cyp154C5. Expres-
sion of CYP154C5 from vector pET28cyp154C5 results in a fusion
protein with N-terminal His-tag.
Generation of CYP154C5 mutants: Mutants were prepared by
QuikChange® site-directed mutagenesis using the Pfu-Turbo Hot-
start PCR Master Mix (Agilent) according to the manufacturer’s
Figure 6. A) Superimposition of the crystal structures of CYP154C with
bound compound 11 (green) and the steroid complexes published under
PDB IDs: 4J6B (1, yellow), 4J6C (3, cyan), 4J6D (5, pink) and 4JBT (4,
magenta). B) Mesh representing a 2Fo  Fc electron density contoured at a σ
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instructions. The primers applied in the PCR reactions are listed in
Table S1 in the supplementary. Correct introduction of the muta-
tions was confirmed by sequencing at GATC Biotech (Konstanz,
Germany) and final plasmids were transformed into E. coli C43(DE3)
for protein expression.
Expression and purification of enzymes: Production of CYP154C5
wild type and its mutants using E. coli C43(DE3), as well as
expression of camA (PdR gene) and camB (Pdx gene) using E. coli
C43(DE3) (pACYCcamA) and E. coli C43(DE3) (pACYCcamB), respec-
tively, were performed as described elsewhere.[11] Protocols for the
production of E. coli C43(DE3) (pIT2cyp154C5) (pACYCcamAB) and
E. coli C43(DE3) (pETcyp154C5-F92A) (pACYCcamAB) whole-cell
biocatalysts were also previously described.[12] Purification of wild-
type CYP154C5 and its mutants via N-terminal His-tag, as well as
purification of PdR and Pdx by anion exchange and hydrophobic
interaction chromatography were also performed as previously
described.[11]
Enzyme assays: The P450 concentration was measured using CO-
difference spectra.[28] The activity of the purified electron transfer
components (ETC) Pdx and PdR was determined by cytochrome c
reduction assay, monitoring the increase in absorbance at 550 nm
of reduced cytochrome c (ɛ450=19.1 mM  1 cm  1) in a mixture
containing a PdR/Pdx ratio of 3 : 16.[29] Additionally, all enzymes
assays were also measured with cell lysate of the respective E. coli
C43(DE3) cells containing P450, PdR and Pdx before whole-cell
catalysis as described elsewhere.[11] Total protein concentration was
determined by Bradford assay.[30]
Substrate binding studies: Dissociation constants (KD) of CYP154C5
wild type and CYP154C5 mutants for the different steroids were
determined by spectroscopic measurements upon titration of
purified P450 with increasing steroid concentrations.[13] Thus,
purified CYP154C5 carrying an N-terminal His tag was diluted with
50 mM potassium phosphate buffer pH 7.4 in order to reach 3 μM
final enzyme concentration. To this mixture, substrate was added in
concentrations from 0 to 150 μM. Therefore, three different
substrate stock solutions of 0.1, 0.5 and 1 mM in 0.1–4.5% (w/v)
hydroxypropyl-β-cyclodextrin in deionized water (diH2O) were
prepared. The absorbance spectra of each sample were measured
on a Cary 50 spectrophotometer (Agilent) between 300 and 500 nm
at 30 °C. As a blank, 3 μM P450 in 50 mM potassium phosphate
buffer, pH 7.4, with addition of an equivalent amount of buffer
instead of substrate solution was used. Each sample was prepared
and measured in duplicate. By plotting the resulting absorbance
difference (Abs386 nm  Abs420 nm) against the applied substrate con-
centration and fitting the data with the tight binding equation
using MATLAB, KD values for the different steroids were
obtained.[31,14]
Turnover number determination: Reactions for the determination
of turnover numbers were carried out in 5 mL scale. Each reaction
contained 3 μM P450, 3 μM PdR, 16 μM Pdx, 0.5 UmL  1 formate
dehydrogenase from C. boidinii, 150 mM sodium formate,
300 UmL  1 catalase from bovine liver, 50 μM NADH and 2 mM of
the respective steroid substrate (1–6) in 50 mM potassium
phosphate buffer pH 7.4. Steroid stock solutions of 4 or 5 mM
concentration were prepared in 1.8–4.5% (w/v) hydroxypropyl-β-
cyclodextrin in diH2O depending on the substrate. All bioconver-
sions were carried out at 30 °C and 250 rpm for up to 20 h. During
bioconversions, samples were taken at different time points for
subsequent HPLC and GC analysis. For that, 0.25 mL of each
reaction was extracted as described elsewhere.[12] Turnover num-
bers were calculated based on substrate consumption and for the
period of time where the highest substrate consumption rate was
observed (usually within the first 2–3 h of reaction). Each reaction
was performed in duplicate.
In contrast, in the case of steroids 10 and 11, TONs were
determined based on whole-cell conversion. When performing
preparative scale reactions of 10 and 11 using frozen cells of E. coli
C43(DE3) (pIT2cyp154C5) (pACYCcamAB), samples were taken over
time and TONs were calculated as described in the previous
paragraph.
Coupling efficiency determination: NADH depletion during bio-
conversions of steroids by CYP154C5 mutants, Pdx and PdR was
monitored in a spectrophotometer at 340 nm (ɛ340=
6.22 mM  1 cm  1). Reactions of 0.7 mL total volume included 0.4 μM
purified P450, 0.4 μM purified PdR, 14 μM purified Pdx, 600 UmL  1
catalase from bovine liver, 200 UmL  1 superoxide dismutase,
200 μM NADH and 1 mM of the respective steroid (4 or 5 mM stock
in 1.8–4.5% (w/v) of hydroxypropyl-β-cyclodextrin in diH2O) in
50 mM potassium phosphate buffer pH 7.4. After the NADH was
completely consumed, 0.5 mL reaction mixture was extracted as
described for the whole-cell catalysis and further analyzed by HPLC
and GC in order to determine the conversion.
Analytical-scale bioconversions: In the case of whole-cell biocon-
versions, frozen cells of E. coli C43(DE3) (pIT2cyp154C5) (pACYCca-
mAB) overexpressing Pdx, PdR and CYP154C5 were resuspended in
50 mM potassium phosphate buffer, pH 7.4, to the desired final
OD600 of 40. All bioconversions were carried out in 1 mL scale at
30 °C and 250 rpm with addition of glucose (0.54 mgmL  1 final
conc.) for cofactor regeneration and 1 mM substrate. Substrate
stock solutions of steroids were prepared in 36% (w/v) hydrox-
ypropyl-β-cyclodextrin in potassium phosphate buffer, pH 7.4. In
detail, stocks with a final concentration of 2.5; 3.2; 4.2; 4.1 and
4.2 mM for substrates finasteride (7), etiadienic acid ethyl ester (8);
ethioallocholane (9); 3-deoxydehydroepiandrostendione (10) and
5α-androstan-3-one (11) were prepared, respectively. Control
reactions were carried out in parallel with E. coli C43(DE3)
(pACYCcamAB) containing only Pdx and PdR. After 20 hours of
reaction, the bioconversions were extracted for subsequent HPLC
and GC analysis. For that, 500 μL of sample was extracted twice
with ethyl acetate (300 μL) and once with chloroform (250 μL). The
organic phases were combined, dried with sodium sulfate and the
solvent was removed under reduced pressure. As an exception,
conversions performed with steroid 8 were acidified with 2 M HCl
previous to the extraction procedure.
Preparative-scale bioconversions: For the conversion of steroids
10 and 11, preparative-scale bioconversions were carried out in
50 mM potassium phosphate buffer, pH 7.4, using resting whole
cells of E. coli C43(DE3) (pIT2cyp154C5) (pACYCcamAB) at 30 °C and
250 rpm with the addition of glucose (0.54 mgmL  1) for cofactor
regeneration. In the case of substrate 10, resting cells were
resuspended in 100 mL buffer to OD600 ~40, equivalent to 7.8 μM
CYP154C5 and an ETC activity of 8.1 UmL  1 (1.1 Umg  1 of total
protein), as determined by CO-difference spectra and cytochrome c
assay, respectively. Similarly, conversion of substrate 11 was
performed using resting cells resuspended in 100 mL buffer to
OD600 ~60, equivalent to 4.2 μM CYP154C5 and an ETC activity of
13.8 UmL  1 (1.4 Umg  1 of total protein). Initial substrate concen-
trations of 1 mM (10 and 11) were used; for that, stock solutions of
substrates 10 and 11 were prepared in 36% (w/v) hydroxypropyl-β-
cyclodextrin (in diH2O) and DMSO, respectively. Preparative-scale
bioconversions of progesterone (3) were carried out in 50 mM
potassium phosphate buffer, pH 7.4, in shake flasks using resting
whole cells of E. coli C43(DE3) (pIT2cyp154C5_F92A) (pACYCcamAB)
at 30 °C and 250 rpm. In this case, cells were resuspended in 80 mL
buffer to OD600 ~40 equivalent to 8 μM CYP154C5 and an ETC
activity of 4.7 UmL  1 (0.6 Umg  1 of total protein), as determined by
CO-difference spectra and cytochrome c assay, respectively. After
24 h of reaction, the complete reaction volume was extracted twice
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(30 mL), the organic phases were combined, dried with sodium
sulfate and the solvent was removed under reduced pressure.
Hydroxylated steroid products were afterwards purified by silica gel
column chromatography with a mixture of ethyl acetate: n-heptane
(8 : 2) as mobile phase.
GC and HPLC analyses: In the case of pregnenolone (1),
dehydroepiandrosterone (2), ethioallocholane (9), 3-deoxydehy-
droepiandrosterone (10) and 5α-androstan-3-one (11), the solid
residues after biocatalysis were redissolved in chloroform contain-
ing 30 mM cholesterol as internal standard. In the case of substrates
etiadienic acid ethyl ester (8), samples were dissolved in pure
chloroform. Samples were analyzed on a GC2010 gas chromato-
graph (Duisburg, Shimadzu) equipped with an OPTIMA 17 ms
column (Macherey-Nagel) with a linear gradient starting at 250 °C
and heating with 10 °Cmin  1 until 300 °C, with the exception of
substrate 9 were the gradient started at 230 °C. Injector and
detector temperature were set to 350 and 300 °C respectively.
Substrates and products were detected by flame ionization
detector (FID). Substrates, pregnenolone (1), dehydroepiandroster-
one (2), etiadienic acid ethyl ester (8), ethioallocholane (9), 3-
deoxydehydroepiandrosterone (10) and 5α-androstan-3-one (11)
were detected with a retention time of 9.69, 7.94, 9.36, 3.87, 4.97
and 5.37 min, respectively, whereas their known products eluted at
9.27 (16α-OH-1), 10.18 (16α-OH-2), 6.14 (16α-OH-10) and 8.24 min
(15α-OH-11), respectively. In the case of substrate finasteride (7),
the solid residue was re-dissolved in chloroform and samples were
analyzed on a GC2010 equipped with a Supreme 5 ms column (CS
Chromatographie Service, Langerwehe, Germany). For separation,
an isothermal temperature program at 300 °C was applied for
20 min. Injector and detector temperature were set to 300 °C.
Substrate 7 was eluted with a retention time of 5.22 min.
The dried residues of bioconversions with progesterone (3),
androstendione (4), testosterone (5) and nandrolone (6) were
dissolved in acetonitrile: water (60 :40) and injected on an ultra-fast
liquid chromatograph (UFLC, Prominence, Shimadzu) equipped
with a Nucleosil 100-5 C18, 250×4.5 mm column at 50 °C.
Acetonitrile/water (60 :40) was used as mobile phase with a flow
rate of 1.2 mLmin  1. Detection of substrates and their respective
products was performed by UV absorbance at 243 (5 and 16α-OH-
5) and 242 nm (3, 4, 6, 16α-OH-3, 16α-OH-4 and 16α-OH-6). The
substrates were eluted at 5.93 min (5), 10.45 min (3), 6.35 min (4)
and 5.39 min (6), whereas the main products were detected at
3.23 min (16α-OH-5), 4.35 min (16α-OH-3), 5.60 min (21-OH-3),
3.87 min (16α-OH-4A) and 3.26 min (16α-OH-6A). In all cases the
conversions were calculated based on substrate consumption.
GC-MS and NMR analyses: Preliminary product identification was
performed with a gas chromatograph - mass spectrometer (GC-MS-
QP2010S, Shimadzu) equipped with an OPTIMA 17 ms column
(Macherey-Nagel) using a linear temperature gradient starting at
250 °C and heating with 10 °Cmin  1 to 300 °C. Injector, interface
and ion source temperature were set to 300, 300 and 200 °C
respectively. Structure elucidation of formed products was per-
formed by 1H, 13C, COSY, HSQC, DEPT and NOESY NMR analysis on
Bruker AV400, AV500 or AV600 instruments using deuterated
chloroform or DMSO as solvent with TMS as internal standard.
Chemical shifts (δ) are given in ppm and coupling constant (J) in
Hz.
MD simulations: Molecular dynamics simulations were performed
by using Yasara with algorithms that were recently described in
detail elsewhere.[32] Periodic boundary conditions were applied.
Long range electrostatics, beyond 7.86 Å, were calculated through
the particle mesh Ewald method using 4th degree spline functions.
The time-step was 2.0 fs, with the nonbonded interactions updated
every two time-steps. The force-field was Yamber3, which is an
Amber99 derivative which was specifically parameterized for
structural accuracy.[33] The compound I structure was generated and
its atomic point charges assigned as described by the Pleiss
group.[34] Point charges on the steroid substrates were generated
with AM1-BCC, which gives similar accuracy as RESP at a much
lower computational cost.[35]
Prior to the MD simulations, an energy minimization (described
previously[36]) was used to remove subtle steric clashes. For each of
the modeled enzyme-substrate complexes, three independent MD
simulations were carried out. These simulations were started with
different initial atom velocities assigned via a random seed
number.[37] The distribution of these atom velocities always obeyed
a Boltzmann distribution. In the first 30 ps of the MD simulation,
the temperature was gradually increased from 5 to 298 K. After
that, the simulation was allowed to equilibrate for 1970 ps. The
subsequent production phase was 20 ns. From the latter phase, all
the reported results were collected. Snapshots were saved every
50 ps.
During the production phase of the MD simulations, geometric
information was recorded to quantify to which extent hydrogen
atoms of the substrate were in a suitable orientation to be attacked
by the oxygen atom of compound I. These geometries were
recorded every 1 ps, on the fly. As suggested by the Bruice group,
near attack conformations (NACs) were defined as having intera-
tomic distances of less than the van der Waals contact distance and
angles between the reacting atoms within 20° of those in the
quantum mechanically modeled transition state (Figure S8).[38,39] A
Yasara script that automatically performs the MD simulations, the
recording of these NACs, and analysis of the resulting data is
available upon request.
Docking: A challenge with the flexible P450 class of enzymes is that
substrate binding often requires small backbone changes. There-
fore, docking was carried out essentially as previously performed by
the Reetz group for modeling steroid binding and conversion by
P450 BM3 variants.[10] First the F92A mutation was introduced into
the four experimentally determined CYP154C5 structures that have
a steroid substrate bound.[11] Subsequently 12 ns MD simulations
were carried out, to sample the possible backbone changes around
the active site. Progesterone was docked to snapshots of these MD
simulations (1 snapshot was used per ns of MD simulation). The
docking was performed using Autodock4[40] with 4995 docking runs
for each snapshot and 25000 energy evaluations per docking run.
Substrate orientations with an unrealistic binding orientation were
avoided by eliminating all poses of which the predicted binding
energy fell outside the 90% confidence interval of the substrate
orientation with the best binding energy, as described earlier.[41]
The same protocol was used for docking steroid 10 as well as 16α-
or 4β-hydroxylated 10 into the active site of CYP154C5 but using
the wild-type structures as starting points.
Protein crystallography: Co-crystallization experiments for wild-
type CYP154C5 with 5α-androstan-3-one (11) were set up using a
HoneyBee 961 pipetting robot (Digilab Genomic Solutions, Hopkin-
ton, USA) mixing 200 nL of protein solution (containing 40 mg/mL
of enzyme and 2 mM of ligand) and 200 nL of reservoir solution,
and monitored with a Rock Imager 1000 automated microscope
(Formulatrix, Bedford, USA). As crystallization trails for wild-type
CYP154C5 based on literature conditions[11] did not directly yield
crystals, sparse matrix screens were applied to identify 0.2 M
ammonium sulfate, 0.1 M BisTris pH 6.5 and 25% (w/v) PEG3350 as
suitable precipitant mixture. Brownish, triangle-shaped crystals
were cryoprotected by soaking in reservoir solution containing
10% (v/v) (R,R)-butane-2,3-diol prior to freezing in liquid nitrogen.
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beamline X06SA (PXI) at the Swiss Light Source (Paul Scherrer
Institut, Villigen, Switzerland) on an EIGER 16M X detector.
Structure determination: Data sets were processed using DIALS,[42]
POINTLESS[43] and AIMLESS[44] of the CCP4 suite[45] applying a
resolution cut-off of 2 Å yielding a CC1/2 higher than 0.5 in the
lowest resolution shell. Initial maps were calculated by Fourier
synthesis using phenix.refine[46] and the atomic coordinates of
CYP154C co-crystalized with testosterone (PDB ID: 4 J6D). The
structure was further refined by alternating rounds of manual
adjustment in COOT[47] and computer-driven refinement with
phenix.refine, including TLS refinement. Geometry restraints for 5α-
androstan-3-one were calculated using the Grade Web Server
(http://grade.globalphasing.org; Global Phasing Inc.). Data process-
ing and refinement statistics are listed in Table S3. Diffraction data
and coordinates were deposited in the Protein Data Bank[48] (PDB
ID: 6TO2).
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